Drug Eluting Stents: An Update With a Focus on Safety

Please note: All assessments are current as of the review date; however, new evidence that may have been published subsequently is not considered.
Review Date: February 28, 2007
Recommendation: This topic was reviewed by the California Technology Assessment Forum on February 28, 2007. The panel determined that: Drug-eluting stents be implanted only in patients who meet current FDA labeling criteria.
Decision: Does Meet CTAF Criteria
Full Assessment: Download (PDF)
History: June 9, 2004: Taxol-based Brug-eluting Stents as an Alternative to Traditional Stenting for Coronary Atherosclerotic Heart Disease (CAD)

Search Assessments

Email Notification

Sign up to receive email notifications of upcoming CTAF meetings and new assessments.

 


Methodology

Learn about CTAF's approach to technology assessment.

Criteria used »
Assessment Process »
Selecting Topics for Assessment »

Suggest an Assessment

Know of a new device, procedure, or test that CTAF should consider for assessment?

Contact us »
  © 2012 California Technology Assessment Forum. All rights reserved.

Contact Us | Privacy Policy | Terms of Use | Credits